Ubiquinone plasma levels are correlated with brain natriuretic peptide plasma levels in patients with chronic heart failure: The potential of coenzyme q10 combined therapy [Povezanost plazma nivoa ubihinona sa nivoem moždanog natriuretskog peptida kod pacijenata sa hronicnom bolešcu srca: Efekti kombinovane terapije koenzimom Q10]

Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combined therapy during a follow-up of 12 weeks. CoQ10 supplementation in HF patients induced improvements in their functional cardiac parameters, such as the ejection fraction. Our results suggest that supplemental CoQ10 may be a useful option for effective management of heart failure and warrant future adequately powered randomized controlled trials of CoQ10 supplementation in patients with HF. © 2018, University of Kragujevac, Faculty of Science. All rights reserved

Gas Transport Characteristics of Hemocorrectors and Perfusates Based on Perfluorocarbon Blood-Substituting Emulsions

This review summarizes the data regarding the gas transport characteristics of hemocorrection and perfusates on the basis of low concentrated drugs nano-sized perfluorocarbonic 20% Perftoran (a blood substitute, it is allowed for clinical use in Russia), 20% Ftoremulsion III (an improved blood substitute, registered in Russia), 10-20% Perfusol (a perfusion solution for perfusion of the isolated heart), 20% Ftorem (a cardioplegic emulsion for surgeries on the stopped heart) used in the biomedical field. The compensation of blood loss using traditional plasma substitutes without the gas transport function or with low gas transport characteristics leads to a decrease in the oxygen capacity of the resulting mixture and subsequently to deterioration in the oxygen transport characteristics of blood. The synthetic gas-transport blood substitutes can be used in the treatment of various forms of ischemia, such as carbon monoxide poisoning. Furthermore, recent results regarding the mechanism of COVID19 infection indicate a possible use of the synthetic gas-transport blood substitutes in the treatment and therapy of COVID19 infected patients

Ubiquinone Plasma Levels are Correlated with Brain Natriuretic Peptide Plasma Levels in Patients with Chronic Heart Failure: The Potential of Coenzyme Q10 Combined Therapy

Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combined therapy during a follow-up of 12 weeks. CoQ10 supplementation in HF patients induced improvements in their functional cardiac parameters, such as the ejection fraction. Our results suggest that supplemental CoQ10 may be a useful option for effective management of heart failure and warrant future adequately powered randomized controlled trials of CoQ10 supplementation in patients with HF

Use of perfluorocarbon based blood substitute perftoran in correction of hypoxia during acute anemia in animals [Upotreba zemene za krv zasnovane na perfluorokarbonu za korigovanje hipoksije tokom akutne anemije kod sisara]

The cause of acute and severe hypoxia of the organism is acute posthemorrhagic anemia. To eliminate posthemorrhagic anemia in animals, the perfluorocarbon blood substitute Perftoran (Russia) with a gas-transporting function was used. The aim of this study was to determine the clinical effectiveness of the perfluorocarbon based blood substitute Perftoran with a gas-carrying function in acute posthemorrhagic anemia in animals and reveal possible side effect of the blood substitute and remove them. In the study conducted in the Clinic of Veterinary Medicine of Pushchino Research Center (Russia) participated 20 cats of both sexes, who were admitted with internal bleeding as a result of injuries. The animals were divided into two groups: the control and the treatment groups (10 per group). All animals with anemia were examined according to the standard scheme: anamnesis vitae and anamnesis morbi, physical examination (basic methods of research were used), additional methods that were used: complete blood count (CBC) and biochemical analysis of blood (BA), microscopy of blood smears, abdominal ultrasonography. Based on the obtained results, we can conclude that the use of the gas-carrying substitute for donor blood Perftoran in the treatment group of animals with posthemorrhagic anemia, which resulted from polytrauma, eliminated tissue hypoxia; the treatment of the animals in the control group with standard solutions (by infusing Stabisol) without gas transport correction led to the development of persistent hypoxia, which persisted to the stage of reticulocyte crisis. © 2019, University of Kragujevac, Faculty of Science. All rights reserved

Use of Perfluorocarbon based Blood Substitute Perftoran in Correction of Hypoxia During Acute Anemia in Animals

The cause of acute and severe hypoxia of the organism is acute posthemorrhagic anemia. To eliminate posthemorrhagic anemia in animals, the perfluorocarbon blood substitute Perftoran (Russia) with a gas-transporting function was used. The aim of this study was to determine the clinical effectiveness of the perfluorocarbon based blood substitute Perftoran with a gas-carrying function in acute posthemorrhagic anemia in animals and reveal possible side effect of the blood substitute and remove them. In the study conducted in the Clinic of Veterinary Medicine of Pushchino Research Center (Russia) participated 20 cats of both sexes, who were admitted with internal bleeding as a result of injuries. The animals were divided into two groups: the control and the treatment groups (10 per group). All animals with anemia were examined according to the standard scheme: anamnesis vitae and anamnesis morbi, physical examination (basic methods of research were used), additional methods that were used: complete blood count (CBC) and biochemical analysis of blood (BA), microscopy of blood smears, abdominal ultrasonography. Based on the obtained results, we can conclude that the use of the gas-carrying substitute for donor blood Perftoran in the treatment group of animals with posthemorrhagic anemia, which resulted from polytrauma, eliminated tissue hypoxia; the treatment of the animals in the control group with standard solutions (by infusing Stabisol) without gas transport correction led to the development of persistent hypoxia, which persisted to the stage of reticulocyte crisis

Ubiquinone plasma levels are correlated with brain natriuretic peptide plasma levels in patients with chronic heart failure: The potential of coenzyme q10 combined therapy [Povezanost plazma nivoa ubihinona sa nivoem moždanog natriuretskog peptida kod pacijenata sa hronicnom bolešcu srca: Efekti kombinovane terapije koenzimom Q10]

Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combined therapy during a follow-up of 12 weeks. CoQ10 supplementation in HF patients induced improvements in their functional cardiac parameters, such as the ejection fraction. Our results suggest that supplemental CoQ10 may be a useful option for effective management of heart failure and warrant future adequately powered randomized controlled trials of CoQ10 supplementation in patients with HF. © 2018, University of Kragujevac, Faculty of Science. All rights reserved